bioMérieux’s New XTRA BioSwab Allows Easier Interpretation of Results
St.Louis, MO - April 3, 2006–bioMérieux INDUSTRY has announced a change in the XTRA BioSwab environmental sampling kit that has increased clarity and allows for easier visual interpretation of growth or no-growth results.
The XTRA BioSwab previously featured two polypropylene sampling tubes. The new sampling tube containing the Tryptic Soy Broth has glass-like clarity due to a change to a K-resin® plastic tube.
The XTRA BioSwab is a ready-to-use test that is comprised of a peel-open pouch containing a sampling swab in a tube with 2 mL of Phosphate Buffer solution and a transport tube with 10mL of Tryptic Soy Broth. The XTRA BioSwab is designed to sample a variety of surface textures and equipment with the advantage of sampling hard-to-reach areas such as equipment crevices and inside pipe work. The double pouch design is gamma-irradiated and VHP-resistant.
About bioMérieux
bioMérieux is a leading international diagnostics group
that specializes in the field of in vitro diagnostics
for clinical and industrial applications. bioMérieux
designs, develops, manufactures and markets systems (i.e. reagents,
instruments and software) used in:
Clinical applications: the diagnosis of infectious
diseases such as hepatitis, HIV, tuberculosis and respiratory
illnesses, as well as pathologies such as cardiovascular diseases
and cancer, based on the analysis of biological samples (such
as blood, saliva or urine); and
Industrial applications: the microbiological
analysis of food, environments (such as water and air), surfaces
and pharmaceutical and cosmetic products, based on the analysis
of product or environmental samples.
In 2005, bioMérieux sales reached 994 million euros.
The company is present in more than 130 countries through 35
subsidiaries and a large network of distributors, which positions
the company well to benefit from the growth potential of the in
vitro diagnostics market. Some important drivers that
underpin this growth are aging populations and age-related
illness, illnesses related to life-style and eating habits,
emerging new pathogens, the development of antibiotic -resistant
bacteria, the fight against bio-terrorism, the recognition
of the importance of the quality of food products. bioMérieux
is listed on the Eurolist of Euronext, Paris (FR0010096479 – BIM).
Other information can be found at www.biomerieux.com
Return to bioMérieux News |
